Candriam SCA’s Forte Biosciences FBRX Stock Holding History

Candriam SCA’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.43M	Buy	303,100 +218,297	+257%	+$5.18M	0.03%	351
2026 Q1	$2.2M	Buy	+84,803	New	+$2.44M	0.01%	508

Other funds holding FBRX

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Candriam SCA's FBRX Position: Q2 2026 in Review

Candriam SCA increased its Forte Biosciences (FBRX) stake by 257% in Q2 2026, buying an estimated $5.18M and bringing the position to 303,100 shares worth $6.43M. The position accounts for 0.03% of the portfolio, ranked #351.

Candriam SCA first reported a position in FBRX in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

Candriam SCA held 303,100 shares of Forte Biosciences worth $6.43M as of Q2 2026.
Candriam SCA bought 218,297 Forte Biosciences shares in Q2 2026, an estimated $5.18M.
Forte Biosciences made up 0.03% of Candriam SCA's portfolio in Q2 2026, its #351 holding.
Candriam SCA first reported a position in Forte Biosciences in Q1 2026 and has held it in 2 quarters since.
86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.